首页> Journal of thoracic disease> Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

导出 OA

翻译打印收藏纠错

第一作者： Yasuhiro,Kato

第一单位： Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Bunkyo, Tokyo, Japan.;Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

作者： Yasuhiro,Kato ^[1] ; Yukio,Hosomi ^[2] ; Kageaki,Watanabe ^[2] ; Makiko,Yomota ^[2] ; Shoko,Kawai ^[2] ; Yusuke,Okuma ^[3] ; Kaoru,Kubota ^[4] ; Masahiro,Seike ^[4] ; Akihiko,Gemma ^[4] ; Tatsuru,Okamura ^[2]

作者单位： Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Bunkyo, Tokyo, Japan.;Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. ^[1] Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Bunkyo, Tokyo, Japan. ^[2] Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Bunkyo, Tokyo, Japan.;Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. ^[3] Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. ^[4]

关键词 EGFR-TKI Lung cancer Threonine790Methionine epidermal growth factor receptor (EGFR)osimertinib

DOI 10.21037/jtd.2019.06.03

PMID 31372272

发布时间 2022-04-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交